HLA-I diversity and tumor mutational burden by comprehensive next-generation sequencing as predictive biomarkers for the treatment of non-small cell lung cancer with PD-(L)1 inhibitors

Immune checkpoint inhibitors (ICIs) improved outcomes in non-small cell lung cancer (NSCLC) patients. We report the predictive utility of human leukocyte antigen class I (HLA-I) diversity and tumor mutational burden (TMB) by comprehensive next-generation sequencing.

Publication year:2022

Keywords:HED, HLA-I diversity, HLA-I evolutionary divergence, Non-small cell lung cancer, PD-1 immunotherapy, TSO500, Tumor mutational burden

Accessibility:Open